At the recent 2013 2013 Genitourinary Cancers Symposium there was an abstract presented that updated data from the COU-AA-302 clinical trial of Abiraterone Acetate (Zytiga) with prednisone. The updated data confirms that Zytiga with prednisone improves overall survival (OS) in men with metastatic castrate resistant prostate cancer (mCRPC) post-docetaxel therapy (chemotherapy)(Lancet Oncol 2012;13:983-92).

The trial evaluated 1088 men who were stratified by Eastern Cooperative Oncology Group performance status (ECOG-PS, 0 vs 1) and randomized 1:1 to Zytiga (AA 1000 mg + P 5 mg po BID) vs Placebo + P. In addition to survival the trial also had
co-primary endpoints: radiographic progression-free survival (rPFS) and OS. Median time with 95% CI was estimated usin